Market Indices
Sector Heatmap
IMNN — Imunon, Inc. Common Stock
NasdaqImunon, Inc. Common Stock
- O
- 1.35
- H
- 1.38
- L
- 1.26
- V
- 94.72K
IMNN — Latest News & Headlines
12 StoriesIDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer - OncLive
IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer OncLive
A debt swap cuts IMUNON’s outstanding debt by about 43%, with no common shares issued. - Stock Titan
A debt swap cuts IMUNON’s outstanding debt by about 43%, with no common shares issued. Stock Titan
Imunon, Inc. (IMNN) Shareholder/Analyst Call - Slideshow (NASDAQ:IMNN) 2026-09-24 - Seeking Alpha
Imunon, Inc. (IMNN) Shareholder/Analyst Call - Slideshow (NASDAQ:IMNN) 2026-09-24 Seeking Alpha
No serious immune-related side effects seen so far in ovarian cancer study - Stock Titan
No serious immune-related side effects seen so far in ovarian cancer study Stock Titan
Imunon Inc. (IMNN) Shares Edge Higher to $1.43 as Stock Presses Against $1.50 Resistance - Low Vol Factor - siam.in
Imunon Inc. (IMNN) Shares Edge Higher to $1.43 as Stock Presses Against $1.50 Resistance - Low Vol Factor siam.in
IMUNON Converts $1.2 Million of Debt-to-Equity - GlobeNewswire
IMUNON Converts $1.2 Million of Debt-to-Equity GlobeNewswire
IMNN 8-K & SEC Filings - Yahoo Finance
IMNN 8-K & SEC Filings Yahoo Finance
A 7,169-share salary award leaves Imunon (IMNN) chair with 103,921 shares held directly. - Stock Titan
A 7,169-share salary award leaves Imunon (IMNN) chair with 103,921 shares held directly. Stock Titan
At $1.41 a share, Imunon (IMNN) granted its medical chief 4,390 shares in place of part of his cash salary. - Stock Titan
At $1.41 a share, Imunon (IMNN) granted its medical chief 4,390 shares in place of part of his cash salary. Stock Titan
Part of the CEO’s salary came as stock: Imunon (IMNN) granted Stacy Lindborg 6,697 shares. - Stock Titan
Part of the CEO’s salary came as stock: Imunon (IMNN) granted Stacy Lindborg 6,697 shares. Stock Titan
A patient in an ovarian cancer trial reports no recurrence nearly 10 years after diagnosis - Stock Titan
A patient in an ovarian cancer trial reports no recurrence nearly 10 years after diagnosis Stock Titan
Imunon Introduces Series B Preferred to Restructure Debt - TipRanks
Imunon Introduces Series B Preferred to Restructure Debt TipRanks